As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Editas Medicine is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Editas Medicine has received a consensus rating of Hold. Get short term trading ideas from the MarketBeat Idea Engine. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.78. link.addEventListener('click', The company's quarterly revenue was up 1532.2% on a year-over-year basis. View all of EDIT's competitors. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. View our earnings forecast for Editas Medicine. The consensus among Wall Street research analysts is that investors should "hold" Editas Medicine stock. Dies and Molds Market in India by End-user and Application - Forecast and Analysis 2021-2025 - The dies and molds market size in India has the potential to … See what's happening in the market right now with MarketBeat's real-time news feed. Learn everything you need to know about successful options trading with this three-part video course. Top institutional shareholders include BlackRock Inc. (8.46%), Sumitomo Mitsui Trust Holdings Inc. (7.00%), Nikko Asset Management Americas Inc. (7.00%), Federated Hermes Inc. (2.74%), Credit Suisse AG (1.35%) and Northern Trust Corp (1.23%). All rights reserved. The Tehran Stock Exchange (TSE) (Persian: بورس اوراق بهادار تهران ‎) is Iran's largest stock exchange, which first opened in 1967. Some companies that are related to Editas Medicine include QIAGEN (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Adaptive Biotechnologies (ADPT), Fate Therapeutics (FATE), Vir Biotechnology (VIR), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Kodiak Sciences (KOD), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Beam Therapeutics (BEAM) and Allogene Therapeutics (ALLO). MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. The official website for Editas Medicine is www.editasmedicine.com. Only 1.80% of the stock of Oceaneering International is held by insiders. Editas Medicine downgraded to market perform from outperform at Raymond James MarketWatch, Gene Therapy Shows Promise for a Form of Blindness, but Is It a Cure? Editas Medicine has a market capitalization of $3.63 billion and generates $20.53 million in revenue each year. Specifically, they have bought $0.00 in company stock and sold $290,732.00 in company stock. View analysts' price targets for Editas Medicine or view top-rated stocks among Wall Street analysts. The company earns $-133,750,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Editas Medicine's stock is owned by a variety of retail and institutional investors. Editas Medicine started at buy with $45 stock price target at SunTrust RH MarketWatch. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Their forecasts range from $14.00 to $86.00. Company insiders that own Editas Medicine stock include Charles Albright, Cynthia Collins, Jessica Hopfield, Michelle Robertson and Vickesh Myer. Sr. Director of Fin. } A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. Privacy Notice, The company can be reached via phone at 617-401-9000 or via email at [email protected]. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. Since then, EDIT stock has increased by 185.8% and is now trading at $57.94. Economic forecasting is the process of making predictions about the economy. Specifically, they have bought $0.00 in company stock and sold $2,005,327.00 in company stock. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. By using this site, you agree to the Subscriber Agreement & Terms of Use, You can edit or delete your press release Online Stock Brokers Market Size And Forecast ... Edit press release. Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. To see all exchange delays and terms of use please see disclaimer. EDIT stock was purchased by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, State of Michigan Retirement System, Cambridge Investment Research Advisors Inc., DDD Partners LLC, Wells Fargo & Company MN, Nia Impact Advisors LLC, Exchange Traded Concepts LLC, and Bank of New York Mellon Corp. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. MarketBeat just released five new trading ideas, but Editas Medicine wasn't one of them. Compare Top Brokerages Here. var link = manageCookies.querySelector('.link'); Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. color: #000066; Want to see which stocks are moving? } The Wall Street Journal Interactive Edition, Nobel Prize in Chemistry Is Awarded for Gene-Editing Technologies The Wall Street Journal Interactive Edition, Editas Medicine price target raised to $65 from $46 at Raymond James, stock rating outperform MarketWatch, How gene therapy and CRISPR are helping to cure blindness MarketWatch, Editas Medicine started at buy with $45 stock price target at SunTrust RH MarketWatch, CRISPR gene-editing technique set to push new boundaries MarketWatch, Editas stock down 21% after announcing CEO departure MarketWatch, Editas Medicine reiterated as buy at SunTrust Robinson Humphrey MarketWatch, Editas Medicine started at outperform with $40 stock price target at Raymond James MarketWatch, CRISPR & Cas Genes Market Future Dynamics and Forecast 2021 to 2026 - Current Industry Trend with Growth Rate, Manufacturing Size, Share and Opportunities, Cost Structure & Production Process Analysis The Express Wire, Dystrophin Market Share 2021 Product Type, Applications, Industry Size, Revenue, Growth Opportunities, Players, Regions and Forecast to 2026 The Express Wire, Duchenne Muscular Dystrophy Drugs Industry Size, Share, Market Segmented by Application, Geography, Global Industry Growth, Historical Analysis, Trends, Emerging Factors, Demands, Key Players, Emerging Technologies and Forecasts 2026 The Express Wire, Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer GlobeNewswire, Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer BusinessWire - BZX, PureTech Founded Entity Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer BusinessWire - BZX, Biotechnology (Synthetic Biology) Market Size, CAGR with Geographical Segmentation, Business Challenges, and Growing Demand Status Forecast to 2025 The Express Wire, Usher Syndrome Threapeutics Market 2021 Business Size, Strategies, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2025 The Express Wire, CRISPR & Cas Genes Market Size 2021, Methodology and Data Source, Market Size Estimation, Research Finding and Conclusion, Future Growth by 2026 The Express Wire, Formalin Market 2021 Development Strategy, Business Prospect, Trends, Manufacturers, Supply, Industry Demand, Growth Factor and Outlook till 2025 The Express Wire, Copyright 2021 MarketWatch, Inc. All rights reserved. Export data to Excel for your own analysis. Editas Medicine's management team includes the following people: Co-Founder & Scientific Advisory Board Member. On January 9, Angeli was arrested and... brought up on U.S. federal charges of "knowingly entering or remaining in any restricted building or grounds without lawful authority, and with violent entry and disorderly conduct on Capitol grounds". View which stocks have been most impacted by COVID-19. You may vote once every thirty days. Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Thursday, November, 5th. View our full suite of financial calendars and market data tables, all for free. Monday, December 31, 2018. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Percentage Held by Institutions. Gene Therapy Shows Promise for a Form of Blindness, but Is It a Cure? The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. View institutional ownership trends for Editas Medicine. High institutional ownership can be a signal of strong market trust in this company. Get daily stock ideas top-performing Wall Street analysts. (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. Shares of EDIT can be purchased through any online brokerage account. function () { window.djcmp.showConsentModal('marketwatch'); }); & Investor Relations, Start Your Risk-Free Trial Subscription Here, 3 Consumer Discretionary Stocks Ready to Run, 3 Dating App Stocks for Investors to Love, Fox hosts Dobbs, Bartiromo strike back in voting fraud suit, Georgia governor urges Biden to block battery maker penalty, Amazon sues NY attorney general to stop virus probe, General Motors settles with California for $5.75M, 3 Oil & Gas Stocks Worth Watching in 2021, U.S. Steel Stock is an Economic Recovery Buy Here, American Axle Manufacturing Stock is an Automotive Recovery and Electrification Play, 3 Health Care Stocks That Could Double by Year End, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, Five things you need to know today, and changes in your inbox, Former Biogen head takes over as CEO of gene-editing firm Editas, Biotechnology (Synthetic Biology) Market Size, CAGR with Geographical Segmentation, Business Challenges, and Growing Demand Status Forecast to 2025, Synthetic Biology Market strategists Key Players, Product and Production Information analysis and forecast to 2025, Can Editas Medicine Stock Bounce Back After A 13% Drop In 5 Days, Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Just Slashed Next Year's Revenue Estimates By 31%, Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why, Editas Medicine (EDIT) Gains As Market Dips: What You Should Know, Despite A 4x Rise, Editas Medicine May Continue To Trend Higher, Editas Medicine stock slumps 15%, chief scientific officer to retire, provides trial updates, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Editas Medicine has received 278 “outperform” votes. Identify stocks that meet your criteria using seven unique stock screeners. if (manageCookies && window.djcmp) { Rachel LevineRachel L. Levine is an American pediatrician who has served as the Pennsylvania Secretary of Health since 2017. ), Editas Medicine has received 382 “underperform” votes. She is a Professor of Pediatrics and Psychiatry at the Penn State College of Medicine, and previously served as the Pennsylvania Physician General from 2015 to 2017. CFO, Principal Accounting Officer, Treasurer & Assistant Sec. In the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Editas Medicine, Inc. operates as a clinical stage genome editing company. Historical and current end-of-day data provided by FACTSET. Wall Street analysts have given Editas Medicine a "Hold" rating, but there may be better short-term opportunities in the market. text-decoration: underline; Do Not Sell My Information. Fundamental company data provided by Zacks Investment Research. Stock quotes by ... Drone market outlook in 2021: industry growth trends, market stats and forecast. Vote “Outperform” if you believe EDIT will outperform the S&P 500 over the long term. (Add your “underperform” vote.). 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. During the same quarter in the previous year, the business posted ($0.66) earnings per share. Looking for new stock ideas? 07:46 AM ET Nobel Prize in Chemistry Is Awarded for Gene-Editing Technologies, How gene therapy and CRISPR are helping to cure blindness, CRISPR gene-editing technique set to push new boundaries, Editas stock down 21% after announcing CEO departure, CRISPR & Cas Genes Market Future Dynamics and Forecast 2021 to 2026 - Current Industry Trend with Growth Rate, Manufacturing Size, Share and Opportunities, Cost Structure & Production Process Analysis, Dystrophin Market Share 2021 Product Type, Applications, Industry Size, Revenue, Growth Opportunities, Players, Regions and Forecast to 2026, Duchenne Muscular Dystrophy Drugs Industry Size, Share, Market Segmented by Application, Geography, Global Industry Growth, Historical Analysis, Trends, Emerging Factors, Demands, Key Players, Emerging Technologies and Forecasts 2026, Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer, Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer, PureTech Founded Entity Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer, Biotechnology (Synthetic Biology) Market Size, CAGR with Geographical Segmentation, Business Challenges, and Growing Demand Status Forecast to 2025, Usher Syndrome Threapeutics Market 2021 Business Size, Strategies, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2025, CRISPR & Cas Genes Market Size 2021, Methodology and Data Source, Market Size Estimation, Research Finding and Conclusion, Future Growth by 2026, Formalin Market 2021 Development Strategy, Business Prospect, Trends, Manufacturers, Supply, Industry Demand, Growth Factor and Outlook till 2025. 09:10 AM ET. This price target is backed by some lofty expectations, including a forecast for Tesla's annual vehicle deliveries to rise from about 500,000 last year to 894,000 this year and 5 million by 2024. Cookie Notice (Manage Cookies) and Your Ad Choices. Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). 11:06 AM ET. View which stocks are hot on social media with MarketBeat's trending stocks report. window.djcmp.gdprApplies('tcfapiOnly', function (gdprApplies) { There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock. Who is Jacob Anthony Chansley? Only 0.94% of the stock of Editas Medicine is held by insiders. 87.52% of the stock of Editas Medicine is held by institutions. a.link:hover { It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. cursor: pointer; EDIT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., BlackRock Inc., Credit Suisse AG, Capital Advisors Inc. OK, Russell Investments Group Ltd., Hussman Strategic Advisors Inc., and Northern Trust Corp. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, Cynthia Collins, and Michelle Robertson. 8 brokers have issued 1-year price objectives for Editas Medicine's stock. View Editas Medicine's earnings history. } The company earned $62.84 million during the quarter, compared to the consensus estimate of $6.36 million. Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT.". Editas Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Vote “Underperform” if you believe EDIT will underperform the S&P 500 over the long term. var manageCookies = document.getElementById('manage-cookies'); text-decoration: none; Learn more. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. Editas Medicine has a P/B Ratio of 11.32. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Please log in to your account or sign up in order to add this asset to your watchlist. This suggests that the stock has a possible downside of 5.9%. USD 374.12 million Growth in Glass Blocks Market during 2021-2025 | Analysis and Forecast of Evolving Opportunities in APAC | Technavio Feb 2, 2021 Feb 2, 2021 Updated Feb 2, 2021 }); The TSE is based in Tehran.As of May 2012, 339 companies with a combined market capitalization of US$104.21 billion were listed on TSE. The company's average rating score is 2.13, and is based on 3 buy ratings, 3 hold ratings, and 2 sell ratings. Tuesday, August 27, 2019. Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. On average, they expect Editas Medicine's share price to reach $54.50 in the next twelve months. Learn more. }. According to analysts' consensus price target of $54.50, Editas Medicine has a forecasted downside of 5.9% from its current price of $57.94. Editas Medicine does not currently pay a dividend. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Editas Medicine had a negative net margin of 99.62% and a negative trailing twelve-month return on equity of 26.74%. Do Not Sell My Personal Information Metal Nitride Nanoparticles Market Growth, Industry, Analysis, Development and Demand Forecast 2020-2027 Today 18:26 EST Noise and Vibration Coatings Market Size, Trends, Growth, Development, Report and Forecast 2020-2027 Editas Medicine employs 208 workers across the globe. Editas Medicine does not have a long track record of dividend growth. One share of EDIT stock can currently be purchased for approximately $57.94. The company issued 5,900,000 shares at $16.00-$18.00 per share. View analyst ratings for Editas Medicine or view top-rated stocks. Receive a free world-class investing education from MarketBeat. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The Wall Street Journal Interactive Edition. a.link { Percentage Held by Insiders. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. CRISPR gene-editing technique set to push new boundaries MarketWatch. View insider buying and selling activity for Editas Medicine or or view top insider-buying stocks. You can edit or delete your press release Sheet Mask Fabrics Market 2021-2025 Analysis & Forecast Report: By Region, Application, Type & Key Players - … Learn about financial terms, types of investments, trading strategies and more. All quotes are in local exchange time. You can opt out at any time. Editas Medicine is headquartered at 11 Hurley Street, Cambridge MA, 02141. Earnings for Editas Medicine are expected to decrease in the coming year, from ($1.78) to ($3.38) per share. EDIT stock was purchased by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, State of Michigan Retirement System, Capital Impact Advisors LLC, Cambridge Investment Research Advisors Inc., DDD Partners LLC, Brevan Howard Capital Management LP, Wells Fargo & Company MN, and Nia Impact Advisors LLC. © American Consumer News, LLC dba MarketBeat® 2010-2021. View insider buying and selling activity for Editas Medicine or view top insider-selling stocks. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Intraday data delayed at least 15 minutes or per exchange requirements. if (gdprApplies) { 83.41% of the stock of Oceaneering International is held by institutions. Intraday Data provided by FACTSET and subject to terms of use. (Add your “outperform” vote. Editas Medicine has received 57.88% “underperform” votes from our community. Editas stock down 21% after announcing CEO departure MarketWatch. The P/E ratio of Editas Medicine is -33.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Tuesday, January 22, 2019.

Anterior Cruciate Ligament Prevents, Tootsie Pop Mini Calories, Thorne: Scaredy Cat, Justin Tesa Wikipedia, Kick The Bucket List, Teacup Puppy For Sale Near Me, Where Is Synergy Furniture Made,